Organoid

Parallel Bio Launches Clinical Trial in a Dish to Speed Drug Discovery

Retrieved on: 
Jeudi, mai 16, 2024
Software, Research, Pharmaceutical, Robotics, Data Management, Technology, Genetics, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, 3D, Patient, Biology, Human, Laboratory, Clinical trial, Immune system, Organoid, FDA, Disease, Lymph, Safety, Drug development, AI, Animal, Drug discovery, Medicine, Cell, Pharmaceutical industry

Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.

Key Points: 
  • Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.
  • Clinical Trial in a Dish creates human models using immune organoids scaled with robotics to represent the biology and diversity of a population.
  • Clinical Trial in a Dish is Parallel Bio’s first commercially available application of its immune system platform, which utilizes lymph-node organoids at scale to replicate the human immune system across diverse populations.
  • Parallel Bio is actively signing on additional pharmaceutical partners for Clinical Trial in a Dish.

HUB Organoids B.V. Awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology

Retrieved on: 
Mardi, mai 14, 2024
Genetic engineering, Health care, Intellectual property, Molecular biology, HUB, Organoid, PDO, Drug development, SAN, Marketing, Frost, Growth, Drug discovery, Social media, Toxicology, DSM-IV codes

SAN ANTONIO, May 14, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award. HUB is a global leader in patient-derived organoid (PDO) technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system.

Key Points: 
  • HUB Organoids Holdings B.V. revolutionizes pre-clinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency.
  • SAN ANTONIO, May 14, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award.
  • As a pioneer in organoid technology, HUB offers transformative solutions to the pharmaceutical industry for more effective, faster, and ethical drug development.
  • HUB develops disruptive PDOs that accurately replicate human drug responses compared to animal models and cell lines, greatly increasing the value and impact of drug development programs.

HUB Organoids B.V. Awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology

Retrieved on: 
Mardi, mai 14, 2024
Genetic engineering, Health care, Intellectual property, Molecular biology, HUB, Organoid, PDO, Drug development, SAN, Marketing, Frost, Growth, Drug discovery, Social media, Toxicology, DSM-IV codes

SAN ANTONIO, May 14, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award. HUB is a global leader in patient-derived organoid (PDO) technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system.

Key Points: 
  • HUB Organoids Holdings B.V. revolutionizes pre-clinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency.
  • SAN ANTONIO, May 14, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award.
  • As a pioneer in organoid technology, HUB offers transformative solutions to the pharmaceutical industry for more effective, faster, and ethical drug development.
  • HUB develops disruptive PDOs that accurately replicate human drug responses compared to animal models and cell lines, greatly increasing the value and impact of drug development programs.

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Mercredi, mai 8, 2024
CTA, CD22, HIP, Contingency, Cell Stem Cell, CD47, Lupus nephritis, Cell, Insulin, Safety, ANCA, Organoid, Research, Survival, Immunosuppression, Research and development, B cell, Development, VIVID, GLEAM, Administration, Autoimmunity, Exercise, Biotechnology, CD19, Patent, Sana, Patient, Regeneration, NHP, Diabetes, Cancer, Lymphoid leukemia, GAAP, Organization, Escape Room, Vaccine

Enrollment in this study continues, and Sana expects to share more data in 2024.

Key Points: 
  • Enrollment in this study continues, and Sana expects to share more data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects to share initial data in the first half of 2024.

Sampling Human Ships its First Kits for Cellular Analysis to Early Access Customers and Releases an App Note with BMG LABTECH

Retrieved on: 
Lundi, mai 6, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, BMG, Cell biology, Single-cell analysis, Luminescence, Apoptosis, Microplate, Organoid, Partnership, Sampling, University, Early access, CBEC, BioRxiv, Student, Drug discovery

Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.

Key Points: 
  • Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.
  • In addition, Sampling Human has partnered with BMG LABTECH to release an application note pairing their kits with BMG LABTECH microplate readers.
  • Daniel Georgiev, co-founder and chief executive officer of Sampling Human, will be speaking on applications for the technology at the SynBioBeta conference.
  • “At Sampling Human, we recognize the great lengths scientists go to today in order to obtain high-quality single-cell data,” said Daniel Georgiev.

Small Molecule Shows Early-Stage Promise for Repairing Myelin Sheath Damage

Retrieved on: 
Jeudi, mai 2, 2024
Nerve, Brain, Enzyme, University, Cell nucleus, Mouse, Tissue, H3K9me3, Organoid, Thought, H3K27ac, Doctor of Philosophy, Axon, Research, Remyelination, Disease, OLS, Cholesterol, Movement, Gene expression, Multiple sclerosis, Regeneration, Ageing, H3K27me3, Tetraplegia, Pharmaceutical industry

CINCINNATI, May 2, 2024 /PRNewswire/ -- When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate vital myelin coatings that protect healthy axon function.

Key Points: 
  • When the protective myelin gets damaged, be it by disease or the wear and tear of age, nerve signaling gets disrupted.
  • Pinning down the genetic changes and signals involved in the repair silencing process and finding a small molecule compound that can reverse the silencing was a complex undertaking.
  • In both aging mice and mice mimicking MS, the ESI1 treatment prompted myelin sheath production and improved lost neurological function.
  • When the organoids were exposed to ESI1, the treatment extended the myelin sheath of myelinating cells, the study reports.

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Retrieved on: 
Mardi, avril 16, 2024
FDA, Genetics, Drug discovery, ADPKD, Mutation, IPS, Food, Prevalence, Proteinuria, Organoid, OTC, Kidney, Gene, Orphan, RNA, Partnership, UPCR, Almirall, U.S. FDA, FAP, IND, RDEB, Disease, SAD, Patient, Biopsy, Clinical trial, Polycystic kidney disease, ODD, Food and Drug Administration, PKD, Pharmaceutical industry

WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided program updates for ELX-02 and ZKN-013, including Orphan Drug Designation (ODD) for ELX-02.

Key Points: 
  • Eloxx has significantly advanced the development of ELX-02 for the treatment of Alport syndrome with Nonsense Mutations (NMAS).
  • “The recent ELX-02 program updates, including Orphan Drug Designation for ELX-02 for the treatment of Alport Syndrome highlights the significant unmet medical needs of Alport Syndrome patients with Nonsense Mutations,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • The designation was based on a review of the prevalence of NMAS and the data from the Proof-of-concept Phase 2 Study that Eloxx announced top-line results for in 2023.
  • In March 2024, Eloxx announced an exclusive license agreement with Almirall to develop and commercialize ZKN-013 in orphan indications including RDEB and FAP with nonsense mutations.

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Vendredi, avril 12, 2024
Education, Alzheimer's disease, Molecular Devices, Merck Group, Investment, Danaher Corporation, Pancreatic cancer, Large intestine, Organoid, Colorectal cancer, Health, Corning Inc., Diabetes, Heart, Biomedical Research, Table, Research, Liver regeneration, Growth, Intelligence, B cell, Disease, Fatty liver disease, Thermo Fisher Scientific, Regenerative medicine, Toxicity, Biology, Drug development, Drug discovery, Government, Hepatitis, Pharmaceutical industry

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.

Key Points: 
  • Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.
  • The key players in the Human Organoids Market include InSphero AG, Corning Incorporated, Molecular Devices, LLC by Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Human Organoids Market.
  • "Dive into the Human Organoids Market Landscape: Explore 190 Pages of Insights, 382 Tables, and 24 Figures"

Human Organoids Market Projected to Reach $2,124.91 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Vendredi, avril 12, 2024
Education, Alzheimer's disease, Molecular Devices, Merck Group, Investment, Danaher Corporation, Pancreatic cancer, Large intestine, Organoid, Colorectal cancer, Health, Corning Inc., Diabetes, Heart, Biomedical Research, Table, Research, Liver regeneration, Growth, Intelligence, B cell, Disease, Fatty liver disease, Thermo Fisher Scientific, Regenerative medicine, Toxicity, Biology, Drug development, Drug discovery, Government, Hepatitis, Pharmaceutical industry

Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.

Key Points: 
  • Human organoids, the three-dimensional construct that simulate the intricate structure and function of human organs, are at the forefront of a revolution in medical research and patient care.
  • The key players in the Human Organoids Market include InSphero AG, Corning Incorporated, Molecular Devices, LLC by Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, and others.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Human Organoids Market.
  • "Dive into the Human Organoids Market Landscape: Explore 190 Pages of Insights, 382 Tables, and 24 Figures"

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

Retrieved on: 
Mercredi, avril 10, 2024
Alzheimer's disease, Architecture, Safety, 3R, Skin, Organoid, Cytokine, Parkinson's disease, Conference, ISO, AAV, Epistasis, B cell, Corporate development, ChromeOS, Retina, Human, Inflammatory bowel disease, Physiology, Lung, Social responsibility, GMP, Drug discovery, CNAS

To propel organoid research, drug discovery, and therapeutic advancements, ACROBiosystems presents the Organoid Toolbox, the comprehensive suite of solutions designed to unlock the potential of organoids across diverse applications.

Key Points: 
  • To propel organoid research, drug discovery, and therapeutic advancements, ACROBiosystems presents the Organoid Toolbox, the comprehensive suite of solutions designed to unlock the potential of organoids across diverse applications.
  • This encompasses ready-to-use organoids, organoid differentiation kits, cytokines for organoid culture, matrix materials for organoid cultivation, organoid differentiation services, and compound testing services on organoids.
  • By leveraging its proprietary organoid research and development platform, the company is seeking to continuously expand its solutions by creating organoids like retina, skin, and lung; thereby broadening the scope of organoid applications.
  • Through advanced in-house organoid differentiation and cryopreservation technologies, ACROBiosystems has achieved pivotal breakthroughs in organoids with conventionally challenging differentiation processes and long maturation periods, delivering highly efficient and user-friendly organoid solutions globally.